Prevalence of Fosfomycin Resistance Among Enterobacterales Isolates in A Tertiary Care Hospital from Turkey
Yeliz Tanrıverdi-Çaycı1, Doğa Beliz Güne2, Mustafa Ertokatlı2
1Department of Medical Microbiology, Ondokuz Mayıs University School of Medicine, Samsun, Turkey.
Objective:
Urinary tract infections are one of the most common causes of morbidity around the world. Fosfomycin is a specific broad-spectrum antibiotic used to treat these infections. However, in recent years, many studies have reported increased fosfomycin resistance in Enterobacterales isolates. Therefore, this study aimed to evaluate the distribution of pathogens isolated from urine samples and find the fosfomycin resistance rates over nine years (2012-2020).
Materials And Methods:
A total of 18,884 uropathogenic Enterobacterales isolates were included in the study between 2012 and 2020. The isolates were identified by VITEK® 2 Compact (bioMérieux, Marcy l'Etoile, France), and the antimicrobial susceptibilities of the isolates were also evaluated using the VITEK® MS automated system (bioMérieux, Marcy l'Etoile, France).
Results:
Escherichia coli (64.04%) was the most common bacteria among Enterobacterales. Fosfomycin resistance rates were 1.98%, 21.64%, and 10.36% in E. coli, Klebsiella pneumoniae, and all bacteria, respectively. The 34.97% of isolates were extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, and the fosfomycin resistance rate was 13.08% in these isolates. In addition, fosfomycin resistance rates were found as 3.06% and 23.84% in ESBL-producing E. coli and ESBL-producing K. pneumoniae, respectively.
Conclusion:
Fosfomycin seems a good option for effectively treating UTIs caused by E. coli. On the other hand, we found that fosfomycin resistance tends to increase over the years. Therefore, we recommend further studies to evaluate fosfomycin resistance.
Insights
Fosfomycin effectively treats urinary tract infections caused by E. coli, but resistance is increasing. This study tracked fosfomycin resistance in Enterobacterales over nine years, revealing concerning trends that warrant further investigation.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Urinary tract infections (UTIs) are a global health concern.
- Fosfomycin is a key antibiotic for treating UTIs.
- Rising fosfomycin resistance in Enterobacterales necessitates monitoring.
Purpose of the Study:
- To analyze the distribution of uropathogenic Enterobacterales.
- To determine fosfomycin resistance rates over nine years (2012-2020).
Main Methods:
- Analysis of 18,884 uropathogenic Enterobacterales isolates.
- Identification and antimicrobial susceptibility testing using VITEK® 2 Compact and VITEK® MS systems.
Main Results:
- Escherichia coli was the most prevalent pathogen (64.04%).
- Overall fosfomycin resistance was 10.36%, with higher rates in Klebsiella pneumoniae (21.64%).
- Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales showed 13.08% fosfomycin resistance.
Conclusions:
- Fosfomycin remains effective against E. coli UTIs.
- A significant increase in fosfomycin resistance was observed over the study period.
- Further research into fosfomycin resistance mechanisms and trends is recommended.
More Related Videos
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Urine Studies II: Urine Culture and Sensitivity Test
Microbiota of the Stomach and Small Intestine
Microbiota of the Large Intestine


